This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

iNova Pharmaceutical's acquisition of Juno PC JV raises Australian competition concerns

( December 19, 2019, 00:28 GMT | Official Statement) -- MLex Summary: iNova Pharmaceutical (Australia)'s plans to buy pharmaceutical joint venture Juno PC have suffered a regulatory setback after Australia's competition regulator announced today that the deal raises competition concerns. In an announcement published alongside a Statement of Issues, the Australian Competition & Consumer Commission said the deal would limit competition in the market for weight loss medication and remove an opportunity for a new product from Juno to enter the market. The ACCC has invited submissions on its concerns by Feb. 7, with a final decision now scheduled for April 9.  The ACCC's full statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections